---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000037"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:52:39.511058+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated

## Summary
- Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.
- Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders ongoing; safety, PK, PD data expected Q4 2025.
- CTA submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes.
- Nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders; GLP tox studies expected 2025.
- Milestone event achieved under Fulcrum license; eligible for $0.6M payment; potential up to $70M in milestones.

## SEC filing metadata
- accession: 0001736730-25-000037
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000037/0001736730-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000037/camp-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000037
- JSON: https://secwatch.observer/filing/0001736730-25-000037.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.